IL132704A - Compounds and method for the inactivation of a virus in a biological composition - Google Patents

Compounds and method for the inactivation of a virus in a biological composition

Info

Publication number
IL132704A
IL132704A IL13270498A IL13270498A IL132704A IL 132704 A IL132704 A IL 132704A IL 13270498 A IL13270498 A IL 13270498A IL 13270498 A IL13270498 A IL 13270498A IL 132704 A IL132704 A IL 132704A
Authority
IL
Israel
Prior art keywords
inactivation
virus
compounds
biological composition
biological
Prior art date
Application number
IL13270498A
Other languages
English (en)
Other versions
IL132704A0 (en
Original Assignee
Vi Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vi Technologies Inc filed Critical Vi Technologies Inc
Publication of IL132704A0 publication Critical patent/IL132704A0/xx
Publication of IL132704A publication Critical patent/IL132704A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A61L2/16—Disinfection or sterilisation of materials or objects, in general; Accessories therefor using chemical substances
    • A61L2/18—Liquid substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/02—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C211/15—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton the carbon skeleton being further substituted by halogen atoms or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D203/00—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08—Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2103/00—Materials or objects being the target of disinfection or sterilisation
    • A61L2103/05—Living organisms or biological materials
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16061—Methods of inactivation or attenuation
    • C12N2760/16063—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL13270498A 1997-05-13 1998-05-13 Compounds and method for the inactivation of a virus in a biological composition IL132704A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/855,378 US6136586A (en) 1995-08-29 1997-05-13 Methods for the selective modification of viral nucleic acids
GB9809724 1998-05-13

Publications (2)

Publication Number Publication Date
IL132704A0 IL132704A0 (en) 2001-03-19
IL132704A true IL132704A (en) 2005-08-31

Family

ID=25321098

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13270498A IL132704A (en) 1997-05-13 1998-05-13 Compounds and method for the inactivation of a virus in a biological composition

Country Status (8)

Country Link
US (1) US6136586A (fr)
EP (1) EP0981511A4 (fr)
JP (1) JP2001524984A (fr)
CN (1) CN1171852C (fr)
AU (1) AU750540B2 (fr)
CA (1) CA2289619A1 (fr)
IL (1) IL132704A (fr)
WO (1) WO1998051660A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
CN1203900C (zh) * 1998-01-06 2005-06-01 塞鲁斯公司 用于淬灭生物材料中病原体灭活剂的方法
US6369048B1 (en) 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
IL146126A0 (en) 1999-04-30 2002-07-25 Slil Biomedical Corp Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases
EP1365750A2 (fr) * 2000-12-21 2003-12-03 Cerus Corporation Procedes d'inactivation de pathogenes dans des matieres biologiques
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
WO2002092806A1 (fr) * 2001-05-15 2002-11-21 V.I. Technologies, Inc. Appareils permettant d'inactiver des pathogenes dans des fluides contenant des proteines
WO2002099073A2 (fr) * 2001-06-06 2002-12-12 V.I. Technologies, Inc Procede d'evaluation de taux de virus infectieux dans un echantillon biologique
US20030130356A1 (en) 2001-10-16 2003-07-10 Slil Biomedical Corporation Oligoamine compounds and derivatives thereof for cancer therapy
JP2005517023A (ja) * 2001-11-06 2005-06-09 ヴイ．アイ．テクノロジーズ，インコーポレーテッド アジリジン化合物の治療的使用
US20040137419A1 (en) * 2003-01-15 2004-07-15 V.I. Technologies, Inc. Methods for removing microbicidal compounds from compositions
US8158102B2 (en) 2003-10-30 2012-04-17 Deka Products Limited Partnership System, device, and method for mixing a substance with a liquid
US7354190B2 (en) 2003-10-30 2008-04-08 Deka Products Limited Partnership Two-stage mixing system, apparatus, and method
US7662139B2 (en) 2003-10-30 2010-02-16 Deka Products Limited Partnership Pump cassette with spiking assembly
AU2005302256B2 (en) * 2004-10-29 2011-01-20 Cerus Corporation Improved quenching methods for red blood cell inactivation process
US8124397B2 (en) * 2005-08-08 2012-02-28 Oregon Health & Science University Inactivating pathogens with oxidizing agents for vaccine production
CA2720824C (fr) 2008-04-09 2021-09-14 Cerus Corporation Procedes ameliores de traitement pour l'inactivation des pathogenes de globules rouges
US8119818B2 (en) 2008-12-04 2012-02-21 E. I. Du Pont De Nemours And Company Functionalized N-substituted pyrrolidonium ionic liquids
US8138354B2 (en) * 2008-12-04 2012-03-20 E. I. Du Pont De Nemours And Company N-substituted pyrrolidonium ionic liquids
JP2012511018A (ja) 2008-12-04 2012-05-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 伸長リンカーを有するｎ−置換ピロリドニウムイオン液体
JP2012510895A (ja) 2008-12-04 2012-05-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 二酸化炭素除去およびこれに有用なイオン液体化合物
US8350056B2 (en) * 2008-12-04 2013-01-08 E I Du Pont De Nemours And Company Functionalized N-substituted pyrrolidonium ionic liquids
CA2826969C (fr) 2010-11-29 2019-02-19 New York Blood Center, Inc. Procede de rassemblement et de stockage de sang
CN106456813B (zh) * 2014-04-15 2020-06-30 勃林格殷格翰国际公司 在制造生物制品期间连续灭活病毒的方法、装置和系统
EP3359641B1 (fr) 2015-10-09 2020-01-08 DEKA Products Limited Partnership Système de bioréacteur et de pompage de fluide
US11299705B2 (en) 2016-11-07 2022-04-12 Deka Products Limited Partnership System and method for creating tissue
EP3562493A1 (fr) 2016-12-31 2019-11-06 Cerus Corporation Compositions et procédés pour la préparation de globules rouges
EP4736892A2 (fr) 2018-09-20 2026-05-06 Cerus Corporation Procédés pour la préparation de sang total inactivé par des agents pathogènes
US12502426B2 (en) 2019-12-16 2025-12-23 Intervet Inc. Inactivated piscine orthoreovirus vaccine
BR112022011330A2 (pt) 2019-12-18 2022-08-23 Intervet Int Bv Vacina contra criptosporidiose
AU2021253605A1 (en) * 2020-04-06 2022-10-06 Valneva Austria Gmbh Inactivated SARS-CoV-2 virus vaccine
KR102922846B1 (ko) * 2020-04-14 2026-02-04 (주)녹십자웰빙 태반추출물을 포함하는 항바이러스 조성물
WO2025264876A1 (fr) 2024-06-20 2025-12-26 Cerus Corporation Systèmes et procédés d'inactivation d'agents pathogènes de produits sanguins

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492289A (en) * 1966-06-13 1970-01-27 Dow Chemical Co Polymers of alkylenimines
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5374424A (en) * 1986-10-03 1994-12-20 Miles Inc. Multivalent felv-infected feline vaccine
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
GB9108682D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Production of vaccines
EP0612532A3 (fr) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Vaccin contre le coronavirus canin à partir de coronavirus entérique félin
US5691132A (en) * 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
EP0773716A4 (fr) * 1995-06-07 1999-08-04 Cerus Corp Traitement de solutions de globules rouges par des agents antiviraux
US6114108A (en) * 1995-08-29 2000-09-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of viral nucleic acids

Also Published As

Publication number Publication date
EP0981511A1 (fr) 2000-03-01
CN1171852C (zh) 2004-10-20
IL132704A0 (en) 2001-03-19
EP0981511A4 (fr) 2000-12-27
AU750540B2 (en) 2002-07-18
CA2289619A1 (fr) 1998-11-19
CN1261873A (zh) 2000-08-02
US6136586A (en) 2000-10-24
WO1998051660A9 (fr) 1999-04-01
WO1998051660A1 (fr) 1998-11-19
JP2001524984A (ja) 2001-12-04
AU7383898A (en) 1998-12-08

Similar Documents

Publication Publication Date Title
IL132704A (en) Compounds and method for the inactivation of a virus in a biological composition
HUP0000808A3 (en) Pharmaceutical composition of fenofibrate and method for preparing same
EP1037635A4 (fr) Composes et procedes
AU8693098A (en) Compositions and methods for treating diabetes
ZA989399B (en) Method and composition
IL136308A0 (en) Antipicornaviral compounds and methods for their use and preparation
HUP9901883A3 (en) Disinfecting composition and process for disinfecting surfaces
EP0980202A4 (fr) Procedes d'inactivation virale et compositions utilisables dans ces procedes
GB2341092B (en) Composition for the removal of biological and organic substances
AU4393497A (en) Method for the sterilization of biological materials
AU1019699A (en) A medicine for treating algomenorrhea and the method of preparation thereof
EP0987942A4 (fr) Composition pharmaceutique et procede d'utilisation
SG65766A1 (en) Composition for preventing and treating gingival diseases
ZA9810982B (en) Process and plant for the reduction of metal-oxide-bearing material
GB9408342D0 (en) Method and composition
GB0112460D0 (en) Decontamination method and composition therefor
GB9707251D0 (en) Novel method and compounds
GB9708400D0 (en) Sterilising arrangement and method
ZA987783B (en) Method and composition for incorporating radiation-absorbing agents into polymers
GB9822065D0 (en) Method and material
GB9419087D0 (en) Method and composition
GB9414888D0 (en) Method and composition
EG22228A (en) Container and coolling method
MD887F1 (en) Immunopotentiator and process for preparation thereof
AU5786798A (en) Method and means for treatment of material

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees